HEXO received no capital injection of cash, they just did a joint venture with Molson Coors, and as a result it did not affect the share price of the stock. Their stock has appreciated due to the company's own efforts and business strategy.
Removing the capital injection that CGC and CRON received, they are still trading at levels above what they were trading at this time last year. It is only ACB that is down due to their "dilution spree", mediocre products, and poor business model.
Market Data 
Markets 
AI
